药物相关性颌骨坏死 (MRONJ) 是服用抗骨吸收或抗血管生成药物的患者的风险。美国口腔颌面外科医师协会 (AAMOS) 对 MRONJ 进行了阶段性分类，以反映疾病的严重程度，并允许实施合适的治疗途径。癌症患者的 MRONJ 风险< 5%，骨质疏松症患者的 MRONJ 风险< 0.05%。随着文献研究佐剂的进展，治疗分为手术治疗和非手术治疗。富含白细胞-血小板的纤维蛋白 (L-PRF) 是一种自体生物材料，由嵌入纤维蛋白基质中的白细胞和血小板组成，能够释放生长因子，促进血管生成、骨再生和软组织愈合。本文的目的是探讨 L-PRF 联合手术清创治疗 MRONJ 的效果。22 例已确诊的 MRONJ 患者接受手术干预（A 组）或手术干预和 L-PRF 治疗（B 组） ），2016 年至 2023 年在爱丁堡牙科学院 (EDI)。当患者无症状、软组织完全愈合、不存在感染/炎症、瘘管或骨骼暴露时，治疗被认为是成功的。B 组的所有病例均已愈合，而 A 组有 54.5% 的病例未愈合； p值 < 0.05表明统计显着性。使用L-PRF作为MRONJ手术治疗的辅助剂因其良好的功能能力、简单的应用和成功的治疗结果而前景广阔。© 2024。作者，独家许可给 Springer-Verlag GmbH 德国（施普林格自然的一部分）。

Medication related osteonecrosis of the jaw (MRONJ) is a risk for patients taking anti-resorptive or anti-angiogenic medications. The American Association of Oral and Maxillofacial Surgeons (AAMOS) has classified MRONJ in stages to reflect the severity of the disease and allows implementation of suitable treatment pathways. MRONJ risk is < 5% in cancer patients and < 0.05% in osteoporosis patients. Management is subdivided into operative and non-operative, with advances in the literature investigating adjuvants. Leukocyte-Platelet Rich Fibrin (L-PRF) is an autologous biomaterial consisting of leukocytes and platelets embedded within a fibrin matrix with the ability to release growth factors enabling angiogenesis, bone regeneration and soft tissue healing. This paper's aim is to investigate the effects of L-PRF in conjuction with surgical debridement for management of MRONJ.Twenty-two cases with established MRONJ were treated with either surgical intervention (Group A) or with surgical intervention and L-PRF (Group B), from 2016 to 2023 at Edinburgh Dental Institute (EDI). Treatments were deemed successful when the patients were asymptomatic, displayed complete soft tissue healing with the absence of infection/inflammation, fistula, or exposed bone.All cases in Group B had healed in contrast to 54.5% not healed in Group A; p value < 0.05 indicating statistical significance.The use of L-PRF as an adjuvant to surgical management of MRONJ is promising with its favourable functional capacity, simple application, and success of treatment outcomes.© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.